Regional Dialysis Center - Rcrh is a medicare approved dialysis facility center in Rapid City, South Dakota and it has 3 dialysis stations. It is located in Pennington county at 353 Fairmont Blvd, Rapid City, SD, 57701. You can reach out to the office of Regional Dialysis Center - Rcrh at (605) 755-2165. This dialysis clinic is run as an Independent entity i.e it is not owned by any chain organization. Regional Dialysis Center - Rcrh has the following ownership type - Non-Profit. It was first certified by medicare in July, 2011. The medicare id for this facility is 432310 and it accepts patients under medicare ESRD program.
| Name | Regional Dialysis Center - Rcrh |
|---|---|
| Location | 353 Fairmont Blvd, Rapid City, South Dakota |
| No. of Dialysis Stations | 3 |
| Medicare ID | 432310 |
| Managed By | Independent |
| Ownership Type | Non-Profit |
| Late Shifts | No |
| 353 Fairmont Blvd, Rapid City, South Dakota, 57701 | |
| (605) 755-2165 | |
| Not Available |
News Archive
New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.
Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.
Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.
› Verified 2 days ago
| NPI Number | 1003145392 |
| Doing Business As | Rapid City Regional Hospital Inc |
| Address | 353 Fairmont Blvd Rapid City, South Dakota, 57701 |
| Phone Number | (605) 719-1000 |
News Archive
New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.
Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.
Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.
› Verified 2 days ago
| Dialysis patients with Hemoglobin data | 6 |
News Archive
New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.
Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.
Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.
› Verified 2 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 94 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 738 |
| Percentage of adult patients getting regular hemodialysis at the center | 90 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.
Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.
Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.
› Verified 2 days ago
| Adult patients getting regular peritoneal dialysis at the center | 1 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 12 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.
Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.
Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.
› Verified 2 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Regional Dialysis Center - Rcrh with elevated calcium levels.
| Patients with hypercalcemia | 100 |
| Hypercalcemia patient months | 817 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 106 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 26 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 21 |
| Patients with Serumphosphor greater than 7 mg/dL | 10 |
News Archive
New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.
Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.
Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.
› Verified 2 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 62 |
| Patient months included in arterial venous fistula and catheter summaries | 139 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 76 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 6 |
News Archive
New research from the Technion-Israel Institute of Technology Rappaport Faculty of Medicine and Research Institute and the Rambam Medical Center may lead to the development of new methods for controlling the growth of cancer, and perhaps lead to treatments that will transform cancer from a lethal disease to a chronic, manageable one, similar to AIDS.
Two separate studies in mice suggest that a class of interferons being evaluated in clinical trials as a therapy for COVID-19 may increase susceptibility to bacterial infections, depending on how long patients are exposed to it, and when they receive it.
Researchers at the University of Birmingham believe that a new method of genetically engineering immune cells could lead to improved treatment of Nasopharyngeal carcinoma (NPC) patients.
Two Indiana University researchers have been awarded a multi-year, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States.
› Verified 2 days ago